The invention aims to provide a biomarker and a corresponding kit based on the enrichment characteristics of secretory cells for individuals with colon cancer. The biomarker allows for improved prognosis and determination of the potential benefits of adjuvant chemotherapy. By quantifying the enrichment patterns of secretory cells in tumor tissue, the biomarker effectively identifies a specific group of colon cancer patients with poor prognosis and limited response to chemotherapy. The accuracy of discrimination in different datasets was found to be 96%. This innovation is significant for clinical detection of colon cancer prognosis and assessment of adjuvant chemotherapy benefits. The third objective of the present invention is to establish a scoring model that utilizes the enrichment characteristics of secretory cells to predict the prognosis and benefits of adjuvant chemotherapy in patients with colon cancer, which is beneficial for predicting the prognosis of patients with non-metastatic cancer and guiding individualized adjuvant chemotherapy for non-metastatic cancer.
SCORING MODEL, CONSTRUCTION METHOD, AND APPLICATION FOR PROGNOSIS AND ADJUVANT CHEMOTHERAPY BENEFITS OF COLON CANCER BASED ON THE ENRICHMENT CHARACTERISTICS OF SECRETORY CELLS
